Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and eribulin in HER2-negative metastatic breast cancer and recurrent ovarian cancer
NCT03430518Phase 1Completed
- Sponsor
- Amy Tiersten
- Start
- May 2018
- Primary completion
- Feb 2020
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of durvalumab in breast cancer, sponsored by Amy Tiersten. Primary endpoint: Dose-Limiting Toxicity Rate at 42 days. Started May 2018; status: completed.
02
Drugs
durvalumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03430518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03430518.